Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 46OTHER 42NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Adrenal Cortex Neoplasms 1

Interventions

Cyclophosphamide 178Radiotherapy 147Paclitaxel 128Carboplatin 124Bevacizumab 123Cisplatin 119Doxorubicin 111Fluorouracil 107Etoposide 102Filgrastim 99Vincristine 88Leucovorin 82Bortezomib 80Gemcitabine 76aldesleukin 74Sorafenib 70Cytarabine 70Taxes 69fludarabine phosphate 67Irinotecan 66Docetaxel 64Oxaliplatin 60sargramostim 58Sirolimus 58temsirolimus 56Erlotinib Hydrochloride 56Methotrexate 55Rituximab 54Vorinostat 52Radiation 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NIH × Axitinib × Clear all
NCT01967576 2021-01-06

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
14 enrolled 12 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT01255137 2013-06-27

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
13 enrolled 9 charts

Adrenal Cortex Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡